This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

WC3079

Allergan plc

Drug Names(s): Mesalamine NextGen, Mesalamine NG, Delzicol NextGen

Description: WC3079 is a next generation formulation of mesalamine (Asacol).

Asacol is thought to be the major therapeutically active part of the sulfasalazine molecule, which is converted to equimolar amounts of sulfapyridine and mesalamine by bacterial action in the colon. The mechanism of action appears to be topical rather than systemic. Mucosal production of arachidonic acide metabolites both through the cyclooxygenase pathways and through the lipoxygenase pathways and hydroxyelcosatetraenoic acids is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Inactive ingredients of Asacol include colloidal silicon dioxide, dibutyl phthalate, edible black ink, iron oxide red, iron oxide yellow, lactose monohydrate, magnesium stearate, methacrylic acid copolymer B (Eudragit S), polyethylene glycol, povidone, sodium starch glycolate, and talc.

Deal Structure: Actavis and Allergan
In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders in June 2015.

Pfizer and Allergan
In November 2015, Pfizer and Allergan announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on November 20, 2015. The transaction represents more than a 30 percent premium based on Pfizers and Allergans unaffected share prices as of October 28, 2015.

Under the terms of the proposed transaction, the businesses...See full deal structure in Biomedtracker


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug